There is evidence in human colon cancer cell lines, colon tumor xenografts, and FGF19 transgenic mice that blocking selectively the interaction of FGF19 and FGFR4 using an anti-FGF19 monoclonal antibody has a potential pharmacological anti-tumorigenic effect [64]. Here, FGF19 is linked to colonic neoplasm.